On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of lungekreft conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes svulst cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanom (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb avslørte at selskapet har sendt inn Opdivos søknad om behandling av lungekreftindikasjoner til FDA og EUs farmasøytiske administrasjon. Det ambisiøse Squibb Company vil naturligvis ikke bare være fornøyd med lungekreft og melanom. Faktisk gjennomfører Squibb for tiden mer enn 35 studier av Opdivo alene eller i kombinasjon med andre medisiner for å behandle forskjellige tumortyper. Ifølge analytikere vil Opdivos fremtidige salg nå så høyt som 5 milliarder amerikanske dollar.
Kreften immunterapi research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Detaljert engelsk rapport:
Bristol-Myers Squibbs ($ BMY) enestående immuno-okologiske legemiddel nivolumab, godkjent forrige måned som Opdivo, oppnådde en rungende suksess i et sent stadium av lungekreftutprøving, og styrket salgsforventningene til den banebrytende behandlingen.
I en studie med 272 pasienter som satte Opdivo opp mot standard kreftdrepende docetaxel, demonstrerte Bristol-Myers-legemidlet så overlegen total overlevelse sammenlignet med kontrollarmen at det nådde sitt primære endepunkt før tidsplanen, og ledet forsøkets dataovervåkingskomités anbefalinger. studien avsluttes tidlig. Bristol-Myers inviterer nå pasientene i docetaxel-gruppen til å velge Opdivo gjennom en åpen utvidelsesstudie.
Bristol-Myers' behandling er utviklet for å galvanisere et immunsystemangrep på svulster ved å blokkere en vei kalt PD-1, som, ukontrollert, lar kreftceller passere uoppdaget av kroppens naturlige forsvar. I likhet med Mercks ($ MRK) lignende Keytruda, vant Opdivo FDA-godkjenning i fjor som en behandling for melanom, men Bristol-Myers' stoff står alene i lungekreft, ettersom dets siste kliniske suksess markerer første gang en PD-1-hemmer har kartlagt en overlevelsesfordel mot sykdommen, sa selskapet.
Opdivo’s particular promise in ikke-småcellet lungekreft has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers har sendt inn søknader om lungekreft i USA og Europa for Opdivo innen lungekreft, og forventer å utvide bruken av stoffet senere i år.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, kreft i hode og nakke, glioblastoma, Non-Hodgkin lymphoma and other cancers.
